US OptionsDetailed Quotes

IPSC241220P2500

Watchlist

1.44
+0.24+20.00%

15min DelayClose Nov 22 16:00 ET

1.44High1.33Low

Century Therapeutics Stock Discussion

Meltyy

May 9 21:51

🚨 April-May 2024 M&A Highlights! 🚨

Keep an eye on these M&As: 👀
Onconova Tx merger w/ Trawsfynydd Tx
$Aditxt (ADTX.US)$ to acquire Appili Tx
TuHURA Biosciences merger w/ $Kintara Therapeutics (KTRA.US)$
$Johnson & Johnson (JNJ.US)$ to acquire $ShockWave Medical (SWAV.US)$
$Vertex Pharmaceuticals (VRTX.US)$ to acquire $Alpine Immune (ALPN.US)$
$Century Therapeutics (IPSC.US)$ to acquire Clade Tx
$Eliem Therapeutics (ELYM.US)$ to acquire Tenet Med.
$Incyte (INCY.US)$ to acquire Escient Pharm.
ONO Pharm to acquire $Deciphera Pharmaceuticals (DCPH.US)$
...

Trytosaveabit

Apr 18 15:58

New 13G

$Century Therapeutics (IPSC.US)$ Century Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Casdin Capital, LLC(6.08%),Eli Casdin(6.08%)

Trytosaveabit

Apr 11 06:04

Update

$Century Therapeutics (IPSC.US)$ Century Therapeutics Strengthens Position In Autoimmune Disease With Strategic Pipeline Expansion Supported By $60 Million Private Placement And Acquisition Of Clade Therapeutics >IPSC
Dow Jones· 3 mins ago

Trytosaveabit

Apr 8 15:12

Watching

$Century Therapeutics (IPSC.US)$ Century Therapeutics Presents New Preclinical Data Highlighting IPSC-Derived Cell Therapy Platform Technology At The 2024 AACR Annual Meeting
Benzinga· 4 mins ago

Moomoo AI

Feb 24 06:49

Insider selling at Century Therapeutics is worrisome despite low volume. Absence of recent insider buying is a negative sign. Yet, insider ownership level shows some alignment between management and smaller shareholders.